

One For All

PHASE
CANCER · RESEARCH · CURE
ONE

17th Annual Gala

April 12th 2017

The Broad Stage

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH.

www.phaseonefoundation.org



In memory of

**BERNARD AND WENDY
GOLDHIRSH,**

the Goldhirsh-Yellin Foundation is thrilled to support

PHASE ONE

and the cutting edge research they make possible--
bringing us all closer to a cure.



ONE FOR ALL

Friends,

We thank you for celebrating with us at the 17th annual PHASE ONE gala. We believe wholeheartedly that the only way a cure to cancer will be found is by joining together as a community and supporting the trials that PHASE ONE has chosen to support and fund.

For this reason, our theme for this year's gala is ONE FOR ALL.

We know you each have your personal story about how this horrible disease has impacted you and the ones you love. We have ours as well, and that is why we know the importance of coming together on an evening like tonight to honor those who are fighting and remembering those we have lost.

We would like to thank our wonderful committee and all the others who worked so hard to make this night such a success. Most of all we would like to thank you for rising up and supporting our fight.

Together we can make a difference.

With love & gratitude,
Janet & Suzette



#PHASEONE #ONEFORALL

GALA COMMITTEE

Janet Lonner, Co-Chair

Suzette Swalwell, Co-Chair

Ashleigh Bergman

Emily Bernstein

Robin Blau

Elizabeth Cohen

Marina Cohn

Leanna Creel

Emily Current

Carly de Castro

Natalie Edmonds

Edyn Elliott Barber

Meritt Elliott

Claire Fair

Stephanie Feder

Marci Foster

Eileen Fracchia

Maryann Gold

Angela Kay

Susan Kurtzman

Brooke Lande

Alyson Fine Marmur

Jodi Meadow

Linda Meadow

Elissa Phillips

Missy Polson

Alisa Rodman

Stephanie Sandler

Tema Schrage

Debbie Silverstein

Michelle Steiner

Anna Suddleson

Linda Toth

Brinley Turner

Nicole Valner

Stacy Valner

Alyssa Weinberger

EVENT COORDINATORS

Grant Associates

INVITATION & JOURNAL DESIGN

Edyn Elliott Barber

A MESSAGE FROM THE CHAIR

Dear PHASE ONE Friends and Family,

On behalf of the Board of Directors, thank you for joining us in support of PHASE ONE's 17th annual gala: ONE FOR ALL. It is because of you that we may continue to fund innovative research and make a difference in the lives of countless individuals and their families.


20 years ago my father was diagnosed with brain cancer. We made the decision to enroll in a phase 1 clinical trial and flew across the country for it knowing it was our best hope not only for my father's survival but for all those in the field trying to learn more about this devastating disease. After 10 months and a fierce battle, my father passed away. The trial gave us hope and after learning the role a phase 1 clinical trial plays, I knew my life would be dedicated to help fund researchers and help ensure patients and families know how to connect with trials available throughout the country. The fight to ensure researchers are funded through the private sector is more important than ever which is why we are here, tonight, arming our passionate researchers and institutions with the tools they need to make progress for ONE, FOR ALL.

After 18 years, PHASE ONE is stronger than ever. The Board of Directors is ready to grow and take PHASE ONE to even greater levels and we hope you will join us in this new chapter. Please take the time to read about the cutting-edge studies we have funded in 2017 further in this journal. Make sure to follow us on social media and join our email list to stay connected with us.

Special thanks to our amazing gala chairs, Janet Lonner and Suzette Swalwell for truly stepping up to the plate and making ONE FOR ALL such a success. Their dedication to PHASE ONE is remarkable and we are blessed to have them on our team.

Again, thank you for being here with us. There would be no ONE FOR ALL without you.

Royce Bergman
Board Chair



#PHASEONE #ONEFORALL

A MESSAGE FROM THE FOUNDERS

Dear Friends,

As many of you know, a little over eighteen years ago, my mother and I were diagnosed with very different types of cancer. Unfortunately for my mother, at the age of 58 and in the epitome of health, she had a type of cancer where little was known, and she was given a year to live.

Nine days later, I was also diagnosed with cancer. Even though my cancer had pretty much spread throughout my body, a lot was known about the type of cancer I had and my odds of survival were more optimistic. After six months of intensive chemotherapy treatments and multiple surgeries, I was told I was “cancer free.” Just a few days later, my mother passed away.

Both my mother and I were treated by some of the best doctors and medical facilities that Southern California has to offer. The primary difference between our illnesses was the knowledge, or lack of that, existed regarding each one of our cancers.

Therefore, seventeen years ago, Stacy and I became determined to make it our mission to raise funds for all types of cancer research. Our hope was that no one should be as unfortunate as my mother was, and that every cancer patient be provided with a sense of hope. A small group of friends joined with us and PHASE ONE was born. Today, this group of people has grown and evolved into a large and diverse one representing all walks of life in our city. I am very proud and thankful for their commitment and leadership. In the last sixteen years, we have funded millions of dollars for cancer research at every major medical center and research facility in our greater Los Angeles community as well as at various other national institutions.


Incredible progress is being made on a daily basis in finding safer and more effective treatments. We are committed to evolving with the speed of technology and recognize how it is becoming an important piece of treating this disease. We are certain that one day cancer will be controlled and ultimately cured in our lifetimes and PHASE ONE is determined to stay in the forefront of this quest.

We thank you for sharing our vision and for your support.

All my best,



Alberto Valner



#PHASEONE #ONEFORALL

WHO WE ARE

BOARD OF DIRECTORS

Royce Bergman, Chair

Diane V. Allen

Crystal Biltz

Jordan R. Bernstein

Leanna Creel

Emily Current

Carly de Castro

Meritt Elliott

Rodney D. Franks

Mark Freeman *

Cecily Jackson-Zapata

Angela Kay

Janet Lonner *

Alyson Fine Marmur

Bradley Meadow

Cary Meadow

Mieke Neumann

Tia Palermo (1959-2012) *

Missy Polson

Steven Romick *

Amanda Salvado, M.D.

Stephanie Sandler

Tema Schrage

Linda Toth

Alberto Valner *

Stacy Valner *

Edward Woods

** Founding Members*

MEDICAL ADVISORY BOARD

Sanaz Memarzadeh, M.D., Ph.D.

Jana L. Portnow, M.D.

Karen L. Reckamp, M.D., M.S.

Antoni Ribas, M.D., Ph.D.

Richard Tuli, M.D., Ph.D.

256 26th Street, Suite 201, Santa Monica, CA 90402

(310)-458-7715 | www.phaseonefoundation.org

Follow us on Facebook, Instagram and Twitter!

@PhaseOneLA



WHAT WE DO

PHASE ONE is a non-profit organization dedicated to supporting Phase I clinical research and treatment programs for patients with cancer. The group was founded in 1999 by Stacy and Alberto Valner, with a small group of friends, all couples with young children. Each one of these individuals had been affected by a diagnosis of cancer in themselves or in a close family member.

Once a new idea or novel drug is identified in the laboratory, the FDA requires three levels of clinical testing prior to the approval of that drug for widespread use. These studies are usually referred to as trials in Phase I, II, or III. The focus of a Phase I trial is to determine the appropriate dose and schedule of a given drug and its side effects. Patients enrolled usually have advanced cancers, which have progressed through standard therapy or for which standard therapy does not exist. Sometimes these patients have been through "everything" and still function extremely well. The Phase II trial applies the Phase I information on dose and schedule and tries to get a hint of efficacy. The Phase III trial is the final set of studies and usually involves hundreds, if not thousands of patients worldwide. Clinical trials are the only way to understand the best and safest therapies available to patients with any disease.

With your support PHASE ONE hopes that its efforts to fund Phase I trials and research will help in the fight against cancer, by finding treatments that will transform what might be a terminal illness into one where patients can live a full and productive life. PHASE ONE is determined to:

- Offer hope to the patient today who has been told there is nothing left.
- Allow patients in our community the access to whatever types of therapy may be available around the world.
- Make the time a patient goes through treatment easier by improving patient care.
- Support research that takes advantage of the vast amount of new information about what causes cancers.
- Lay the groundwork for larger scale multi-center research that can set new standards of oncology care.
- Make sure that those diagnosed with cancer in the future will have even safer and more effective treatments to live long lives with their disease too.

Since 1999, PHASE ONE has raised more than \$16 million in support of these trials and programs at some of the most prestigious organizations in Southern California including Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, City of Hope, UCLA Jonsson Comprehensive Cancer Center, USC/Norris Comprehensive Cancer Center, Children's Hospital of Los Angeles and the Premiere Oncology Foundation Lung Cancer Initiative.

#PHASEONE #ONEFORALL

WHAT WE SUPPORT

Dedicated to ensuring that the Southern California community has access to the most promising novel therapies available for those afflicted with cancer, PHASE ONE directs its efforts to support research that might not be funded by alternative mechanisms.

The studies selected include novel therapies and conventional ones, all having some scientific question about efficacy, biologic correlates, surrogate markers (radiographic, laboratory, tissue based or other), or mechanism of action. The findings of these studies will ideally lead to further research or further independently-funded projects.

2017

Dr. Akil Merchant, USC Norris Comprehensive Cancer Center

Grant Amount: \$320,000

Adult acute leukemia remains a deadly disease for which new treatments are urgently needed. Both common types of acute leukemia, acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), can be treated with chemotherapy, which induces remission in many patients; however, the leukemia almost always relapses, and most patients with relapsed disease have only months to live, making the need for new treatments for relapsed leukemia particularly critical.

EphB4, a protein that is found in many types of cancer including leukemia, promotes cancer growth. By targeting EphB4, we aim to reduce the growth of leukemia cells and make the cancer more sensitive to chemotherapy. USC has developed an agent, sEphB4-HSA, that can target EphB4 in patients. This agent has been tested in Phase 1 and 2 clinical trials for patients with different types of tumors and was found to be safe, with some patients having a dramatic response to the drug. In addition, Dr. Akil Merchant's team has demonstrated in pre-clinical studies that this strategy is effective against EphB4-positive leukemia. In this study, we are testing sEphB4-HSA in combination with chemotherapy to determine if these medicines can be given safely together and if they are more effective against leukemia than chemotherapy alone. Ultimately, we hope to translate sEphB4-HSA into safer and more effective treatment for patients with relapsed leukemia.

Dr. Mina S. Sedrak, Department of Medical Oncology & Therapeutics Research, City of Hope

Grant Amount \$58,080

The purpose of this trial is to conduct multidisciplinary research to understand how social media can enhance the public's knowledge, health behaviors, and outcomes as it relates to cancer. City of Hope's goal is to understand the use and limits of the new and rapidly evolving modes of participative communication as they apply to cancer research. They strive to bring scientific rigor and insight to study online communication and social networks, develop new tools and methods for mining the cancer ecosystem online, and understand how interpersonal connections influence personal health choices and actions.

Clinical trials are essential for translating scientific discoveries into new treatments, but only 3 percent to 4 percent of adult cancer patients participate annually in therapeutic clinical trials. Strategies that aim to inform and educate the public on the condition being studied have been linked to improvements in patient recruitment. How people get information is changing dramatically and it may be necessary to use new modes of online communication through social media to tap into health communication effectively. Numerous cancer care organizations and campaigns have recently used Twitter as a media platform for health promotion and education. Despite an apparent increase in use, there remains a paucity of literature examining the content of Twitter in cancer care or even the extent to which Twitter provides useful information about a subject as complex as cancer. There is a need to improve understanding of existing cancer communications on social media sites such as Twitter to better utilize these sites to deliver information about cancer. These insights, in turn, would allow the design of targeted interventions on social media to promote clinical trial participation.

The use of social media for cancer research is in its infancy. Its value and direct application remains to be seen and warrants further exploration. The proposed research their lab aims to do is highly innovative because, just like the medium itself, the tools used to conduct social media research are incompletely characterized and evolving. Analysis of Twitter data, for example, represents an important opportunity for the cancer community, but it also presents a number of very unique challenges. Because this area of research is so new, there are few standardized metrics or research approaches. City of Hope aims to learn how the public uses Twitter to get information about cancer. These insights will lead to novel approaches for dissemination of information to improve treatment and support for cancer patients and survivors, and create improved public awareness of clinical trials. This work will provide the essential foundation for further research in this new area.

Dr. Yuan Yuan, City of Hope

Grant Amount \$150,655

Triple negative breast cancers (TNBC) (estrogen, progesterone and HER2 negative), are typically not responsive to targeted therapies, can be more aggressive, and are more likely to recur than other breast cancer subtypes. To counter these challenges, TNBCs have been suggested to be promising targets for immunotherapy, as well as targeting the Androgen Receptor in Androgen Receptor Positive TNBC, after it was found that this tumor type is highly infiltrated by immune cells. Extending the reach of a current phase 2 study for treating these patients with a combination of immunotherapy along with the androgen receptor modulator, this work will analyze immune cell characteristics and biomarkers before and after treatment in order to predict response. Once these predictive biomarkers are identified, this will help assess patient's response and potential efficacy of immunotherapy.

2016

Dr. Araz Marachelian, Children's Hospital Los Angeles

Grant Amount: \$61,416

Neuroblastoma is the most common extra-cranial solid tumor in children. Patients with high-risk features continue to have an expected survival of 50% despite intensive therapy. The addition of immunotherapy utilizing the recently FDA approved anti-GD2 mAb ch14.18 Unituxin has improved outcome. However, long-term disease free survival remains a significant problem and improving immunotherapy further is needed for complete disease eradication. Adoptive immunotherapy with natural killer (NK) cells has emerged as a promising anti-cancer treatment with broad anti-cancer potential. Until recently, the clinical efficacy and effective application of NK cell immunotherapy has been limited by the inability to obtain sufficient cell numbers for adoptive transfer. We have developed a novel expansion method for NK cells that solves this problem using artificial antigen presenting cells to express stimulatory molecules that promote sustained proliferation of NK cells in the laboratory. This expansion can be performed from blood from a simple venipuncture that can then be sent to the central laboratory. This phase 1 study will be the first study to combine cellular therapy with Unituxin in the treatment of patients during which we will identify the maximum tolerated dose of NK cells to be given with Unituxin and determine the immune effects of the combination therapy for patients with neuroblastoma. It will also be the first multi-center pediatric trial with cellular therapy and will help pave the way for other cellular therapy trials in pediatrics. The trial will be conducted through the NANT consortium (NANT.org), a multi-institution consortium (centered at CHLA) whose goal is identify new therapies for patients with relapsed and refractory neuroblastoma and to improve their outcome. If successful, this therapy could then be utilized for all high-risk neuroblastoma patients to eradicate residual disease. The cost of this trial exceeds \$1 million, but funding from Phase One foundation would be used as a component of the budget.

2015

Dr. Sanaz Memarzadeh, UCLA Broad Stem Cell Research Center

Grant Amount: \$456,000

Sanaz Memarzadeh, MD, PhD, presented an opportunity for PHASE ONE to support a truly novel and promising ovarian cancer research study at the UCLA Broad Stem Cell Research Center. We are pleased to announce our two-year commitment of \$300,000 in support of this innovative new approach. In addition, supporters pledged “I DO” and joined us by directly adding their own donations to her work using smartphones at our 15th Annual Gala or donating online, bringing in an additional \$156,000.

Ovarian tumors account for about 3% of all malignancies in women, but are responsible for a disproportionately large number of cancer-related deaths. Ovarian cancer research has been chronically underfunded, compounding the challenge and perpetuating the risk to women. PHASE ONE’s grant will have a significant impact in beginning to reverse this situation.

Ovarian cancers are particularly dangerous because they are detected late. Ovarian cancer symptoms are often non-specific and can resemble other common ailments. Incredibly, there is no definitive screening test for ovarian cancer; tumors cannot be detected at an early stage.

We now know that most, if not all, cancers arise from cancer stem cells. Conventional therapies target rapidly dividing tumor cells, but cancer stem cells have the means to escape chemo and radiation. At some point, the cancer stem cells begin to self-renew, creating a new tumor.

The standard of care is surgical removal followed by chemotherapy. However, most patients relapse within one year and many succumb to ovarian cancer within five years. These tumors contain cells that exhibit stem cell-like properties and resist existing therapies. While these cells are a tiny fraction of the tumor mass, they are entirely responsible for initiating its regrowth.

Dr. Memarzadeh and her team have made major progress in isolating these stem cell-like catalysts, and are testing ways of eliminating them through enhanced chemotherapy. They envision a handful of strategies to individualize a patient’s care based on tumor analysis. With support from PHASE ONE, Dr. Memarzadeh is moving the first of these therapeutic strategies into clinical trial.

“My experience caring for patients with ovarian and other gynecological cancers is what motivates me to find more effective treatments to replace or compliment conventional therapies,” said Dr. Memarzadeh.

Testicular Cancer Awareness Initiative of the Adolescent and Young Adult Cancer Program at USC

Grant Amount: \$25,000

When longtime board member and former chair Tia Palermo passed away in 2012 following an 11-year battle with cancer, her family joined PHASE ONE in raising funds for a multi-million dollar endowment in her memory. Funds from “PHASE ONE’s Tia Palermo Memorial Endowment” support three different programs:

- Tia’s Hope (www.tiashope.org), which provides gifts and support to children at hospitals throughout the country,
- PHASE ONE grants that it funds within the foundation’s original mission
- Small size grants that typically do not exceed \$50,000 to support research, treatment and cancer awareness programs in our community that can be outside of the original PHASE ONE mission.

PHASE ONE’s first endowment grant was made in 2015 to the USC Norris Adolescent and Young Adult (AYA) cancer program’s new testicular cancer awareness initiative. The initiative is a collaborative community project with the Los Angeles Unified School District (LAUSD) and the University of Southern California (USC).

With the funds from the PHASE ONE grant, in the fall of 2015, AYA initiated a pilot program with the LAUSD and USC aimed at increasing awareness of testicular cancer and among school-age students. In the past several decades, cancers occurring in childhood have been the focus of cancer research and treatment programs worldwide. Unfortunately less attention has been given to adolescent and young adult (AYA) patients (ages 15-39) and cancer remains the number one disease killer within this age group. Because testicular cancer is one of the most common cancers diagnosed in young men, increasing awareness and early detection is a top educational priority of the initiative.

LAUSD is the nation’s second largest school district with an annual enrollment of approximately 651,000 kids in 1,188 schools. The district provides a semester-long comprehensive health education courses to all Grade 7 and 9 students who attend its schools. The courses are taught by credentialed health teachers. While the currently adopted curriculum used by the LAUSD health course contains content related to testicular cancer, the health textbook is ten years old, which is three years past a standard new adoption.

The initiative developed new project based health lessons focused on testicular cancer awareness to complement the current LAUSD health curriculum. Following the completion of the testicular cancer curriculum, professional development, technical assistance, and follow up support to the LAUSD health educators on project and content as they implement and incorporate these materials into their program, is planned. The newly developed curriculum was then piloted in the fall of 2015 in a minimum of three schools with the goal of expanding it to additional schools the following year and ultimately to every school in the LAUSD system.

2014

Dr. Richard Tuli, Cedars-Sinai Medical Center

Grant Amount: \$323,423

Pancreatic adenocarcinoma is a devastating disease with the lowest survival rate of any solid cancer. Gemcitabine chemotherapy and radiotherapy given concurrently remain the mainstay treatments for patients with locally advanced pancreatic cancer, which cannot be removed by surgery, but also has not spread to other areas of the body. Both gemcitabine and radiotherapy kill tumor cells by interfering with their DNA, the genetic blueprint. Veliparib is a poly (ADP-ribose) polymerase (PARP)1/2 inhibitor; PARP1/2 proteins are also involved in DNA repair. Studies have shown that inhibiting PARP1/2 activity can significantly enhance the effects of radiotherapy and chemotherapy in killing tumor cells. Our own laboratory work has shown excellent synergy between veliparib (a PARP inhibitor), radiotherapy and gemcitabine in killing pancreatic cancer cells grown in culture, and in prolonging survival in mice with pancreatic tumors.

Based upon these promising results and with the generous support of the PHASE ONE Foundation and Diane V. Allen, we are currently enrolling patients in a first-in-human, investigational clinical study (phase I) to test the safety and efficacy of veliparib in combination with gemcitabine and radiotherapy in patients with locally advanced pancreatic cancer. Prior to and during therapy, patient tumor and blood samples will also be tested for levels of different DNA repair proteins and mutations, such as BRCA1/2. This molecular “signature” will hopefully serve as a “biomarker” to predict how the patient and tumor are responding to treatment. We are hopeful that we will be able to select out the subset of favorable patients who respond to this regimen, and design future studies (phase 2/3) by “personalizing” treatments using PARP1/2 inhibitors.

Dr. Jana Portnow, City of Hope

Grant Amount: \$66,000

Dr. Jana Portnow has been the fortunate recipient of prior funding from the PHASE ONE Foundation in support of two important brain tumor research projects. One of these projects involved developing a technique to measure chemotherapy levels in brain tumor patients using microdialysis catheters. Dr. Portnow’s other ongoing research interest is taking into clinical trials a promising new treatment for gliomas that involves the use of genetically-modified human neural stem cells as vehicles for drug delivery to the brain.

The brain tumor research team at City of Hope modified an established human neural stem cell line to carry an enzyme called cytosine deaminase (CD) which can convert an inactive prodrug, 5-fluorocytosine (5-FC), to the chemotherapy agent 5-fluorouracil (5-FU). With support from the PHASE ONE Foundation, Dr. Portnow performed a first-in-human study of these CD-expressing neural stem cells in combination with oral 5-FC in patients with recurrent high-grade gliomas.

Based on the results of this pilot-feasibility study, Dr. Portnow is performing a formal phase I study of these CD-expressing neural stem cells in combination with oral 5-FC in patients with recurrent high grade gliomas. In addition to escalating the dose of neural stem cells, this study will assess the feasibility of giving repeat doses of neural stem cells through an indwelling catheter which will be placed at the time of surgery.

Guests at the 2014 Gala donated \$66,000 toward that study, and the first patient was enrolled this fall.

2013

Dr. Karim Chamie, University of California Los Angeles

Grant Amount: \$142,350

Dr. Karim Chamie, with UCLA Urology, is working to combat the rapid increase in recent years of urothelial cancer by investigating a potentially new treatment method involving a hydrogel polymer (chemical compound), which is liquid at room temperature, mixed with chemotherapy to treat this difficult-to-detect and highly reoccurring form of cancer. The polymer-chemotherapy combination takes on the shape of the cavity of interest (such as a kidney) at body temperature and has the potential to deliver chemotherapy to the targeted site while minimizing side-effects. The polymer can also be mixed with a dye that binds to tumor cells to facilitate detection of tumor cells within a specific organ. Traditionally, what has been most challenging in treating this type of cancer is the ability to deliver the chemotherapeutic agent at a high concentration level to the exact tumor site. This new discovery has the potential to overcome the previous challenge by using the polymer-chemotherapy directly to the targeted site. Dr. Chamie and his team are optimistic in pursuing this study and are grateful to the PHASE ONE Foundation for supporting these efforts.

Dr. Joseph Riss, University of California Los Angeles

Grant Amount: \$310,000

Despite advancement in targeted treatments, metastatic kidney cancer poses a therapeutic challenge due to its resistance to conventional models of treatment. As long-term survival for patients with metastatic kidney cancer remains poor, UCLA Urology's Allan Pantuck, MD and Arie Beldegrun, MD, along with Joseph Riss, PhD, have been working for years to develop innovative methods of therapy. With the assistance of critical funding provided by the PHASE ONE Foundation, this research team developed a kidney cancer vaccine that was recently approved by the FDA and given to the first patient in February 2013. Even with this grand milestone, the researchers must now monitor the effectiveness of the vaccine, especially given the kidney tumor's resistance to current therapeutics. With the continuous support of the PHASE ONE Foundation, Dr. Riss and his team will use previously identified indicators to develop diagnostic tools for monitoring the new treatment and aim to develop a next-generation vaccine that will combat tumor resistance in metastatic kidney cancer.

Dr. Anna Pawlowska, City of Hope

Grant Amount: \$37,000

Ewing's sarcoma is the second most common primary bone tumor in children and adolescents. While advances in treatment have increased survival rates for children with localized disease to nearly 70 percent, fewer than 30 percent of patients who experience relapse or the spread of their cancer survive. In addition to these grim statistics, there is no nationally accepted "gold standard" of treatment for patients with advanced Ewing's sarcoma. More effective therapies are urgently needed to save the lives of young patients.

City of Hope will launch a five-year pilot clinical trial to study the effectiveness of a promising treatment for high-risk patients with advanced Ewing's sarcoma: whole-body MRI-guided radiation therapy followed by autologous hematopoietic cell transplant, with a novel combination of high-dose chemotherapy. The proposed study will assess whether this therapy is feasible, safe and likely to increase patient survival rates. A similar approach tested in Germany and Austria increased children's survival rate to 70 percent after two years and 56 percent after three years with minimal toxicity, but this approach has never been tested in the United States.

Guests at the 2013 PHASE ONE Gala directly donated \$37,000 to help fund part of this five-year trial by supporting MRI tests for patients not covered by their insurance and/or support a portion of the salary of a Clinical Research Assistant. This critical seed funding would help young patients with Ewing's sarcoma access a promising new therapy now and start collecting the patient data needed to secure additional public and private funding for future years of the trial.

2012

Dr. Antoni Ribas, University of California Los Angeles

Grant Amount: \$294,400

With the support of PHASE ONE, we will conduct a phase I clinical trial (MART-1 F5 TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade) with the goal of genetically programming the human immune system to efficiently target cancer cells in patients with advanced stage melanoma, the deadliest of skin cancers. This clinical trial builds upon the experience at UCLA over the past 3 years in the use of T cell receptor (TCR) engineered adoptive cell transfer therapy. This therapy is manufactured in-house and results in the generation of a large army of immune system cells that are genetically redirected to recognize and kill melanoma. With this therapy we have noted high initial response rates, but tumors come back. A major limitation has been a progressive decrease in the antitumor functionality of the TCR engineered immune cells. The antibody tremelimumab blocks a major negative regulator in immune cells and will be tested with the goal of maintaining the cancer killing functionality of the TCR engineered lymphocytes given to patients. This protocol has administrative approval by the UCLA regulatory committees and it has already been filed and approved by the Food and Drug Administration.

Hamamatsu NanoZoomer 2.0 HT Slide Scanner, City of Hope

Grant Amount: \$75,000

PHASE ONE board member and former chair, Tia Palermo, passed away in 2012 following an 11-year battle with cancer. PHASE ONE wanted to honor her memory, and along with generous donations from friends and family, funded an extraordinary piece of equipment called the Hamamatsu NanoZoomer 2.0 HT-slide scanner at City of Hope, where Tia had been treated.

The T Cell Therapeutic Research Laboratory (TCTRL), directed by Tia's physician Dr. Stephen Forman, is developing novel immune-based therapies for the treatment of cancer—specifically for the treatment of hematological malignancies, gynecological cancers and brain tumors. Their pre-clinical and clinical research program focuses on engineering human T cells to recognize and destroy tumor cells, and, in first-in-human clinical trials, in which a patient's own reprogrammed tumor-specific T cells are transferred back to that patient, have observed encouraging initial results.

A current technical challenge for the research program is the high-throughput evaluation of human and mouse tumor and organ histology both before and after therapeutic intervention with T cells that have been genetically modified to attack tumors. To address this technical limitation, the goal was to purchase the Hamamatsu NanoZoomer 2.0-HT slide scanner (C9600-13) with fluorescence imaging module (L11600-21). This equipment will help evaluate the amount of T cell and/or tumor cell engraftment in their in vivo models of cancer therapy, and the surface marker/antigen profiles of individual cells both in their in vivo cancer models as well as on primary human tumor samples. Specifically, this slide scanner and imager will provide cell-level resolution critical for determining the frequencies of varying patterns of antigen expression, mapping antigen distributions between cells and on individual cells both before and after adoptive T cell therapy in clinical trials and/or animal experiments.

The Hamamatsu unit combines high capacity (210 slides per run) for array tomography mapping of antigen expression relative to tumor structures, high resolution (0.46 $\mu\text{m}/\text{pixel}$ or 0.23 $\mu\text{m}/\text{pixel}$), and high sensitivity with relatively increased speed with TDI (Time Delay Integration) line scanning. Cell-level resolution is critical for determining frequencies of varying patterns of antigen expression, mapping antigen distributions between cells and on individual cells. The COH Light Microscope and Digital Imaging Core, while well-equipped for conventional confocal microscopy, lacks the capability for scanning wide fields at high spatial resolution and high-throughput. Overall, this slide scanner and imaging unit is extremely important for their research mission of developing cancer immunotherapies.

2011

**Dr. P.R. Lowenstein and Dr. Maria G. Castro, Department of Neurosurgery and Cell and Developmental Biology,
The University of Michigan School of Medicine
Grant Amount \$216,000**

Highly malignant brain tumors are uniformly lethal. Patients usually survive less than 2 years post-diagnosis, with very few still alive 5 years later. In spite of constant developments in surgery, radiotherapy and chemotherapy a breakthrough for this particularly aggressive cancer has not been yet discovered. Over the last ten years we have developed a novel approach for the treatment of brain tumors. Based on an evolutionary and developmental understanding of the structure and function of the brain immune system, we decided to reconstitute to the brain those immune cells normally absent from it, as a potential new approach to treat brain tumors.

The immune cells normally absent from the brain are those in charge of turning on the anti-tumor immune response. Their absence from the brain helps us explain why normally anti-brain tumor immune responses are ineffective. By attracting those specific immune cells to the brain and the brain tumors, we expect them to identify brain tumor antigens and unleash a therapeutically effective immune attack to eliminate brain tumors. To achieve this we have turned adenoviruses which normally can cause lung infections and other diseases into therapeutic agents. We have engineered the viruses to deliver directly to the brain and the brain tumors a protein that will recruit the missing immune cells to the brain to start a clinically effective immune response. As our work uses viruses as agents of treatment to induce immune responses, our therapeutic approach is described as a “combined gene-and immune therapy”.

Following more than ten years of development and experimental testing we are now ready to start clinical trials in patients suffering from glioblastoma multiforme. With very generous support from the PHASE ONE Foundation, we are now on the threshold of starting the first ever clinical trials of this new therapeutic approach for the treatment of deadly highly malignant brain tumors. The proposed trial, which was approved by the Food and Drug Administration on April 7, 2011, is currently undergoing the final evaluations by the Institutional Biosafety Committee, and the Institutional Review Board for Clinical Trials. We expect these evaluations to be finalized within the next few weeks. Once our trial has cleared all necessary Committee reviews, it will be ready to start. PHASE ONE has thus provided the green light to move the dreams of two basic scientists into the challenging arena of clinical trials. As the trial starts enrolling patients we will look forward to keeping PHASE ONE abreast of all therapeutic developments. We hope, and for the sake of the patients, we pray, that treating the first patients may represent in Winston Churchill’s prophetic words, “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”

2010

Dr. Stuart E. Siegel, Children's Hospital Los Angeles

Grant Amount: \$410,000

In February 2010, PHASE ONE announced a grant, \$410,000 over two years, to fund a Phase I study at Children's Hospital Los Angeles. The study, led by Dr. Stuart E. Siegel, is of AC220 for children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This grant will provide an opportunity in getting a second generation FLT3 inhibitor drug tested in a pediatric population that truly focuses on the concept of FLT3 inhibition in high-risk ALL and AML patients. The goal of the study is to obtain sufficient laboratory and clinical data to enable the design of a larger Phase II study. Results from this study would also leverage funding to support the Phase II part of this project from both the National Cancer Institute, as well as the pharmaceutical company Ambit that makes the drug.

2009

The Premiere Oncology Foundation Lung Cancer Initiative

Grant Amount: \$266,500

Premiere Oncology Foundation, a non-profit dedicated to cancer research, integrative medicine, patient/family support services and community education, will utilize the grant to support a comprehensive lung cancer program to include multi-disciplinary research.

Lung cancer is the world's top cancer killer, claiming more than 1.3 million lives per year, yet few financial resources have been dedicated to this disease. The Premiere Oncology Foundation Lung Cancer Initiative focuses on the use of FDA-sanctioned novel treatment regimens in collaboration with experts in the field of lung cancer detection and treatment. The program will foster dialog among practitioners caring for lung cancer patients, and provide a means for seamless interaction with medical and radiation oncologists, thoracic surgeons, radiologists, pulmonologists and primary care physicians caring for these patients.

2007-2008

The Samuel Oschin Comprehensive Cancer Institute-Cedars-Sinai Medical Center

Grant Amount: \$2,000,000

Internationally renowned cancer researcher Steven Piantadosi, MD, PhD, was named the inaugural PHASE ONE Foundation Endowed Chair of the Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center at a ceremony February 6, 2008. SOCCI provides cutting edge cancer clinical trials and sub-cellular research, in addition to state-of-the-art patient care. Its research efforts are focused on developing breakthroughs that translate as efficiently as possible into new methods for the treatment of cancers of the lung, brain, colon, prostate, pancreas, breast, spine, ovaries, pituitary, thyroid and blood system, plus melanoma and other cancers.

With this endowment, Dr. Piantadosi will define and direct the activities of the Institute and serve as a key figure in framing the national debate about cancer, while having a decided impact on the direction and success of new research.

2007-2008

City of Hope Comprehensive Cancer Center

Grant Amount: \$345,000

The City of Hope Division of Medical Oncology, Chaired by Robert Figlin MD., and its Department of Clinical and Molecular Pharmacology, directed by Yun Yen MD, PhD., is the City of Hope Comprehensive Cancer Center equivalent to a Phase 1 Solid Tumor Program. In this program is the exciting translation of molecules from the laboratory to the clinic.

City of Hope will use the PHASE ONE funds to support novel Phase 1 clinical trials developed in collaboration with the Department of Clinical and Molecular Pharmacology. These resources would be utilized to fund novel protocols or existing protocols where additional funds could translate findings from the laboratory to the clinic. Support for novel "NEW" programs (25-50K/year for two years) in Clinical and Molecular Pharmacology that can reach the clinic during the two years of the award, and bring innovation from our laboratories will be the highest priority.

The City of Hope Comprehensive Cancer Center's Phase1 Program has a commitment to the Developmental Therapeutics and Hematologic Malignancies Programs directed by Yun Yen MD, PhD, Richard Jove PhD, and Steven Forman MD. City of Hope will establish competitive awards (25-50K/year for two years) that combine a laboratory and clinical Principal Investigator that translate laboratory observations into the clinic during this period. Programs in Solid Tumors and Hematologic Malignancies including lymphomas, in both adults and children would be included.

2006

Dr. Kuk-Wha Lee

Grant Amount: \$250,000

Dr. Lee is a graduate of the Medical Scientist Training program at Loma Linda University School of Medicine, obtaining her PhD and MD. Her clinical training is in pediatrics and she was fellowship trained in Pediatric Endocrinology at the Mattel Children's Hospital at UCLA. In training she was the recipient of the prestigious Giannini Foundation Fellowship, Stein-Oppenheimer Award, and the LWPES Clinical Scholar Award for her research. In addition, she is the recipient of the UCLA Prostate Cancer SPORE Career Development Award for her research in cellular and animal models of human prostate cancer.

Her laboratory studies the biological functions of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) and its binding partners in cancer biology, specifically prostate cancer. Specifically, she studies the molecular mechanisms by which this molecule enters cells; targets specific areas within cancer cells (e.g. the nucleus and mitochondria); and initiates the programmed cell death cascade.

Unique assays in their laboratory have been developed to study serum levels of these molecules and also have developed unique transgenic and knockout mouse models of human disease. Based on preliminary work published from their laboratory the plan is to initiate a phase 1 trial of IGFBP-3 in men with prostate cancer in the near future.

2005

Dr. Karen Reckamp, A Phase 1 Trial of Vaccine Therapy with Lung Cancer

Grant Amount: \$500,000

Internationally renowned cancer researcher Steven Piantadosi, MD, PhD, was named the inaugural PHASE ONE Foundation Endowed Chair of the Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center at a ceremony February 6, 2008. SOCCI provides cutting edge cancer clinical trials and sub-cellular research, in addition to state-of-the-art patient care. Its research efforts are focused on developing breakthroughs that translate as efficiently as possible into new methods for the treatment of cancers of the lung, brain, colon, prostate, pancreas, breast, spine, ovaries, pituitary, thyroid and blood system, plus melanoma and other cancers.

With this endowment, Dr. Piantadosi will define and direct the activities of the Institute and serve as a key figure in framing the national debate about cancer, while having a decided impact on the direction and success of new research.

2004

Dr. Arie Belldegrun & Dr. Alan Pantuck

Grant Amount: \$250,000

UCLA Department of Urology Specializing in New Treatments for Kidney and other genitourinary cancers, particularly vaccine therapies directed against newly identified targets.

Dr. Heinz-Josef Lenz & Dr. Daniel Vallboehmer

Grant Amount: \$250,000

USC/Norris Comprehensive Cancer Center Specialists In Gastro-Intestinal Malignancy Searching for molecular markers to predict prognosis and response to therapy.

Dr. Charles Sawyers & Dr. Ingo Mellinghoff
Grant Amount: \$250,000

UCLA Jonsson Comprehensive Cancer Center Hematology/Oncology Translational Scientists working on molecular mechanisms that underlie the development and spread of cancer.

Dr. David Agus & Dr. Mitchell Gross
Grant Amount: \$250,000

Cedars-Sinai Prostate Cancer Program Looking at innovative treatments for prostate cancer and using information technology systems to identify molecular markers for response to therapy.

2003

Dr. Lee Rosen, Cancer Institute Medical Group
Grant Amount: \$276,250

In 2003, Dr. Lee Rosen conducted a Phase I study of a medication that could theoretically shut down the development of new blood vessels from which tumors grow and possibly spread. Using a series of radiographic assessments including CT/MRI/Bone scans, etc. as well as conventional scans such as CT/MRI, Dr. Rosen and his colleagues at the Cancer Institute Medical Group, examined the response of their patients to this new medication and to what degree. He also found the use of PET scans, which look at changes in tumor metabolic activity rather than size, is very effective, PHASE ONE has been sponsoring a trial which will look at whether a combination of PET/CT scans can aid in the assessment of the drug's efficacy more quickly than conventional CT scanning alone.

2002

Dr. Sven de Vos, Dr. Christos Emmanouilides, Dr. William H. McBride and Dr. Jonathan W. Said, Jonsson Comprehensive Cancer Center

Grant Amount: \$150,000

PHASE ONE sponsored an Indisciplinary Grant to study the use of the Proteasome Inhibitor PS-341 in the treatment of refractory diffuse large B-cell lymphomas in terms of clinical efficacy, mechanisms of resistance and new models of combination therapy. The study was conducted by principal investigator, Sven de Vos, M.D., and co-investigators, Christos Emmanouilides, M.D., William H. McBride, M.D. and Jonathan W. Said, M.D. at the Jonsson Comprehensive Cancer Center.

2001

Dr. Carolyn Britten, Jonsson Comprehensive Cancer Center

Grant Amount: \$175,000

PHASE ONE sponsored the recruitment of a full-time clinical research physician for a full year. Highly respected oncologist, Dr. Carolyn Britten, joined the faculty of the Jonsson Comprehensive Cancer Center in early 2001 and PHASE ONE funded her research for one year. Dr. Britten is involved in four promising Phase I trials testing new and unique therapeutic strategies in signal transduction and angiogenesis.

MEDICAL ADVISORY BOARD



Sanaz Memarzadeh, M.D., Ph.D.

Professor, Department of Obstetrics and Gynecology
Member, JCCC Cancer and Stem Cell Biology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California

DR. SANAZ MEMARZADEH, MD, PhD is a board-certified clinician and scientist who treats patients with ovarian and endometrial cancers in the clinic and operating room. In addition, she is the Director and Principal Investigator of an independent research laboratory, the G.O. Discovery Lab, at UCLA. She earned both an undergraduate and medical degree at the University of Pittsburgh. After medical school, she came to UCLA for her OB-GYN residency where she became passionate about caring for women with gynecologic cancers. There, she realized a vital need for basic science research to help improve current therapies and early detection. She pursued a clinical fellowship in gynecologic oncology and simultaneously began her training as a basic scientist, completing her fellowship and PhD training within eight years.

She is deeply passionate about being a woman clinician-scientist who works both at the bedside and the bench. Working directly with patients has provided her an acute perspective on the shortcomings of early detection and treatment for women with gynecologic cancers. In fact, every question asked in her laboratory is born out of an important and unanswered question from the clinic.

With her many affiliations including Professorship at UCLA's David Geffen School of Medicine, a clinical practice out of Ronald Regan Medical Center and the West Los Angeles Veterans Administration Hospital, the Eli and Edythe Broad Center of Regenerative Medicine, the Jonsson Comprehensive Cancer Center, and the UCLA Molecular Biology Institute, she is primed to effectively use basic science research to improve gynecologic cancer treatments, which have seen little change in the past few decades. Her career goal is to develop more effective and less toxic therapies for women impacted by gynecologic cancers and, importantly, also help train the next generations of scientists that will revolutionize medicine as practiced today.



Jana Portnow, M.D.

Associate Clinical Professor, Department of Medical Oncology & Therapeutics ; Associate Director, Brain Tumor Program; Medical Oncologist; City of Hope Comprehensive Cancer Center, Duarte, California

"I want to help people battling brain cancer as much as I can."

A key member of the City of Hope team since 2002, JANA PORTNOW, M.D., feels a special affinity for patients with brain cancer, even though she often seems to be giving them bad news. "They are grateful for what I do for them and surprisingly not resentful that their prognosis is not good," she says.

Dr. Portnow is heavily involved in research to improve treatment of the most aggressive and difficult brain cancers. She is investigating the use of microdialysis to monitor a drug's effectiveness as well as the application of neural stem cells to deliver chemotherapy directly into inoperable tumors. Also, Dr. Portnow is examining immunotherapy options including a clinical trial using specially modified T-cells.

Dr. Portnow received her medical degree from the University of Rochester, and completed residencies and fellowships at Temple University and Johns Hopkins University. A native New Yorker, Dr. Portnow calls City of Hope "a wonderful place to work. The atmosphere is collegial and supportive, which is not always the case in research institutions."



Karen L. Reckamp, M.D., M.S.

Medical Director of Clinical Research Operations
City of Hope Comprehensive Cancer Center
Beckman Research Institute, Duarte, California

KAREN L. RECKAMP, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. She received her medical degree from University of Chicago, and her master's degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital, and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Her activities at City of Hope include Medical Director of Clinical Operations, Medical Director of the Thoracic Oncology program and Chair of the COHCCC scientific review committee. She is a member of the NCCN Lung Cancer, Thymic Malignancies and Mesothelioma Guidelines Committees. She serves as principal investigator for many Phase I, II and III studies funded by the NCI, internal funds and industry. Dr. Reckamp is a member of ASCO, AACR, International Association for the Study of Lung Cancer, and SWOG. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. Dr. Reckamp has been the past recipient of many honors including Phase I Clinical Investigator Award in 2006 and ASCO/AACR Methods in Clinical Cancer Research Workshop in 2003. She has also authored or co-authored many manuscripts in the field of Thoracic Oncology.



Antoni Ribas, M.D., Ph.D.

Professor, Departments of Medicine, Surgery, and Molecular and Medical Pharmacology; Director, Parker Institute for Cancer Immunotherapy Center at UCLA Director; JCCC Tumor Immunology Program Member; JCCC Signal Transduction and Therapeutics Program; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

ANTONI RIBAS, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. He is an elected member of the American Society of Clinical Investigation (ASCI) and is the recipient of a NCI Outstanding Investigator Award. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. His NIH, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients.



Richard Tuli, M.D., Ph.D.

Assistant Clinical Professor, Clinical Genetics and Dymorphology
Assistant Clinical Professor, Digestive and Liver Diseases
Assistant Professor, Radiation Oncology
Assistant Professor, Biomedical Sciences
Cedars-Sinai Medical Center, Los Angeles, California

RICHARD TULI, M.D., Ph.D., is an attending radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Cancer Institute. Tuli's clinical and research interests are in gastrointestinal (GI) oncology. He is active in developing the multidisciplinary management of GI cancer patients. His research interests include investigating novel radiotherapy techniques to improve outcomes and minimize toxicity, and identifying radiosensitizing agents for treating cancer. Current research is directed toward PARP inhibitors, immunotherapies and other novel drugs in combination with radiation. Tuli has published over 140 research articles, abstracts and book chapters. His research has appeared in several peer-reviewed journals. His awards include the ASCO Cancer Foundation Merit Award, AACR Scholar-in-Training Award and Hyman Menduke Research Prize. Tuli is a member of professional organizations including the American Society for Radiation Oncology, the American Society of Clinical Oncology and the American Association for Cancer Research. In addition to presenting his research at numerous national and international conferences, Tuli serves as a manuscript reviewer for peer-reviewed journals. After earning his medical degree from Jefferson Medical College, he completed his residency in radiation oncology at Johns Hopkins Hospital, where he served as chief resident. Tuli completed a pre-doctoral fellowship at the National Institutes of Health.

CANCER RESOURCES



(310) 458-7715

www.phaseonefoundation.org

256 26th Street, Suite 201, Santa Monica, CA 90402

A FRESH CHAPTER
(310) 458-7715
www.afreshchapter.com

AMERICAN CANCER SOCIETY
(800) 227-2345
www.cancer.org

**CEDARS-SINAI SAMUEL OSCHIN
COMPREHENSIVE CANCER INSTITUTE**
(310) 423-8030
www.cedars-sinai.edu

CHAI LIFELINE
(877) 242-4543
www.chailifeline.org

**CHILDREN'S HOSPITAL LOS ANGELES
CENTER FOR CANCER & BLOOD DISEASES**
(323) 669-2121
www.chla.org

CITY OF HOPE
(626) 359-8111
www.cityofhope.org

**PANCREATIC CANCER ACTION NETWORK
(PanCAN)**
(310) 791-5214 or (877) 272-6226
www.pancan.org

TIA'S HOPE
www.tiashope.org
info@tiashope.com

**JOHN WAYNE CANCER INSTITUTE
AT SAINT JOHN'S HOSPITAL & HEALTH CENTER**
(800) 262-6259
www.jwci.org

**UCLA JONSSON COMPREHENSIVE
CANCER CENTER**
(310) 825-5268
www.cancer.ucla.edu

**USC/NORRIS COMPREHENSIVE CANCER
CENTER & HOSPITAL**
(800) 872-2273
(323) 865-3000
<http://uscnorriscancer.usc.edu>

VITAL OPTIONS INTERNATIONAL
"The Group Room"
(818) 508-5657
www.vitaloptions.org
Cancer Support Community

BENJAMIN CENTER
(formerly The Wellness Community)
(310) 314-2555
www.cancersupportcommunitybenjamincenter.org

#PHASEONE #ONEFORALL

HEARTFELT THANKS

PHASE ONE SPONSOR

Elizabeth Goldhirsh

VISIONARY SPONSORS

Iris & Michael Smith

CURE SPONSORS

Cedars-Sinai Medical Center

Holly & Tom Gores

Heather Reid & Allison Milgard

Ellen & Richard Sandler

January & Edward Woods

HEALER SPONSORS

Pam & Alan Bergman

Ashleigh & Royce Bergman

Bari Milken Bernstein & Fred J. Bernstein

Valerie & Charles Black

Judy & Bernard Briskin

Carly & Alejandro de Castro

The Duhl Foundation

Marci & Greg Foster

Jill & Mark Freeman

Cindy & Jerry Kay

Bobby Kotick

Kaye & Jeremy Kramer

Mickey & Steve Lewis

Janet Lonner

David Lonner, Oasis Media Group

Mieke & Spencer Neumann

Maya & Jeff Pinkner

Eden & Steve Romick

Dena & Irv Schechter & Family

Reagan Silber

Rae & Bruce Tobey


Stacy & Alberto Valner

#PHASEONE #ONEFORALL

PHASE
ONE

**VISIONARY
SPONSOR**

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH



To the dedicated
Doctors, Volunteers, and Committee Members
of the PHASE ONE Foundation,

Your fervent dedication in raising funds and awareness for cancer clinical research and treatment is inspiring.

These acts bring forth true feelings of both the fragility and strength of humanity in us all.

We commend you for your accomplishments and wish the team continued success.

With enormous respect,

Iris and Michael Smith

Tara and Brian Swibel

Kaily and Adam Westbrook

THANK YOU

Janet and Suzette

**FOR TAKING ON THIS MASSIVE ENDEAVOR.
CONGRATULATIONS!**

**PHASE ONE
BOARD OF DIRECTORS**



Mom,

**You continually amaze us with your strength, resilience, and love.
We couldn't be prouder!**

Love, Jordan, Matthew, Adam, and Sydney

Suzette:

We are so proud you embraced the challenge of co-chairing this year's PHASE ONE event in addition to your usual "duties" as the best and most amazing wife and mom ever.

Now, go have a cocktail and enjoy with everyone else!

Love,

Nicole, Michael and CS



PHASE
ONE

CURE
SPONSOR

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH

IT TAKES EACH OF US TO MAKE A DIFFERENCE FOR ALL OF US.

CEDARS-SINAI IS PROUD TO PARTNER WITH PHASE ONE ON
CUTTING-EDGE RESEARCH IN THE FIGHT AGAINST CANCER.

CONGRATULATIONS ON YOUR 17TH ANNUAL GALA.



CEDARS-SINAI[®]

SAMUEL OSCHIN
COMPREHENSIVE CANCER INSTITUTE



January and Eddie Woods

gratefully support PHASE ONE

and its brilliant grantees who are moving forward

to find the causes and cures for cancer.

Thank you to everyone who gives to make this possible.



IN MEMORY OF

Noreen Fraser

Thank you for being a CHAMPION
for cancer patients everywhere.

Your POSITIVITY and PASSION
will continue to inspire the world.

YOU ARE MISSED.

To The Gala Committee

Ashleigh Bergman
Emily Bernstein
Robin Blau
Elizabeth Cohen
Marina Cohn
Leanna Creel
Emily Current
Carly de Castro
Natalie Edmonds

Edyn Elliott Barber
Meritt Elliott
Stephanie Feder
Marci Foster
Eileen Fracchia
Maryann Gold
Angela Kay
Susan Kurtzman
Brooke Lande

Alyson Fine Marmur
Jodi Meadow
Linda Meadow
Elissa Phillips
Missy Polson
Alisa Rodman
Stephanie Sandler
Tema Schrage

Debbie Silverstein
Michelle Steiner
Anna Suddleson
Linda Toth
Brinley Turner
Nicole Valner
Stacy Valner
Alyssa Weinberger

And special thanks to our Junior Committee

Niki Valner, Claire Fair, Stephanie Feder, Ashlie Sapiro, Mallory Kugler,

**We thank you for all your hard work, inviting all your friends, attending meetings,
and inspiring us with creative ideas to make this gala a success.**

Janet and Suzette

LEANNA

Thank you for your

VISION

DEDICATION

PASSION

FRIENDSHIP

We would be lost without you!

PHASE ONE BOARD OF DIRECTORS

Thank You Creel Studios

**AARON ANDERSEN
LEANNA CREEL
CHRISTIAN EVANS
MAUREEN FLANNIGAN**

**RINAT GREENBERG
DHEVI NATARAJAN
HEATHER REID**

**DILLON SCHNEIDER
CANAAN TRIPLETT
TOM ZEHNDER**

And Our Featured Cancer Fighters

**ALEXANDRA HEDISON
MARGARET STEFFEN**

**BROOKE WEISBARTH
DR. YUAN YUAN**

*... for another incredible video. We cannot thank you enough
for your creativity and hard work!*

PHASE ONE BOARD OF DIRECTORS



Dear Claire,

You saved the day, literally today!
There would be no gala tonight without you!
I am so lucky you joined the team (me)!
Thank you for jumping on when I needed you the most!
You're the best and I'm so proud of you!

Love,
Stacy






THANK YOU TO WEXLER'S DELI FOR SUPPORTING PHASE ONE!

PHASE
ONE

**LIFESAVER
SPONSOR**

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH



For all the lives you touch every day we are so grateful and so very proud of you.

**With Love,
Ashleigh, Greyson and Mom**

ALL FOR ONE AND ONE FOR ALL!



WE ARE HONORED TO SUPPORT
AND STAND TOGETHER WITH

PHASE ONE

IN THE FIGHT AGAINST CANCER
AND THE HOPE OF A CURE.




JUDY & BERNIE BRISKIN



**Honoring the extraordinary work and
accomplishments of Phase One.**

David Lonner



We applaud your dedication
to supporting innovative
Phase 1 clinical research
and treatment programs



**MILKEN FAMILY
FOUNDATION**

Leading Advances in Education,
Medical Research and Public Health

We are proud to support

PHASE ONE

and its continued


search for a cure.

Eden and Steven Romick

PHASE ONE
is kicking it!

Keep on kicking,

The Schechter Family



Janet and Suzette,
WHAT A RIDE IT'S BEEN!
YOU TWO MADE

**One
For
All**

A HIT!!!
FOREVER IN DEBT!

Love, Stacy



Five years without
Tia is five years
too many.

We miss you
everyday.

PHASE ONE
Board of Directors



**DADDY,
YOU ARE OUR HERO.
YOU MAKE OUR
DREAMS COME TRUE.**

**STACY, SOPHIA, NIKI,
HARRISON, LUCY**

In loving memory of

KEVIN CARLBERG



PHASE ONE BOARD OF
DIRECTORS



ROYCE-

THANK YOU FOR BECOMING **THE ONE**

WHO WILL MAKE

PHASE ONE FOR ALL AGAIN!

HERE'S TO THE BEST FUTURE FOR **PHASE ONE!**

STACY AND ALBERTO VALNER

Always in our hearts.



*Alberto, Stacy, Sophia, Nicole,
Harrison, and Lucy*

ROYCE

Thanks for being our fearless leader!

PHASE ONE BOARD OF DIRECTORS



Kathryn,

We will
forever fight
on in your
memory!

Stacy

PHASE
ONE

HEALER
SPONSOR

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH



IN LOVING MEMORY OF



Meg Mazursky

CARLY & ALEJANDRO DE CASTRO

Janet & Suzette,

Congratulations on a fabulous event...
you two worked your *magic* to make tonight
"ONE FOR ALL!"

*XOXO,
Marci & Greg*

**We are so proud of
the PHASE ONE Board of Directors
lead by Royce Bergman
to reinvigorate and push forward to beat the
F#*k out of cancer.**

PHASE ONE ROCKS.

THANK YOU to EVERYONE who supports our efforts.

**LOVE,
Jill Roberts-Freeman and Mark Freeman**

**Congratulations to all at
PHASE ONE!**



Cindy and Jerry Kay



Love,
THE LEWIS
CLAN



**WE ARE PROUD
TO ALWAYS SUPPORT
PHASE ONE!**

THE LONNER FAMILY

Janet, Jordan, Adam, Matthew & Sydney

Dear Stacy and Alberto,

Thank you for your tireless dedication to finding a cure!



Love,
Mieke and Spencer




TO PHASE ONE -

**WITH ADMIRATION AND GRATITUDE
FOR ALL YOU'VE ACCOMPLISHED AND
ALL THE LIVES YOU'VE TOUCHED.**

You inspire us!

**PAM AND ALAN BERGMAN
MAYA AND JEFF PINKNER
RAE AND BRUCE TOBEY**



In memory of our friend,
Tia Palermo Ravich,
who left us too soon
and cared so much about
PHASE ONE
and in honor of tonight's Co-Chair,
Janet Lonner.

Thanks for all you do,
David A. and Karen Richards Sachs

**IT IS A PRIVILEGE TO SUPPORT
THE WONDERFUL WORK OF PHASE ONE
AND A SPECIAL THANK YOU TO
STEPHANIE AND MARINA
FOR THEIR EXEMPLARY EFFORTS
ON BEHALF OF THIS ORGANIZATION.**

Ellen and Richard Sandler



It is our honor to support the

PHASE

CANCER RESEARCH CURE

ONE

17th Annual Gala

We applaud their dedication to cancer research and treatment programs.

Patty & Greg Penske

longotoyota.com | longolexus.com

Edyn Elliott Barber,

**Thank you for your amazing creativity
and continued support.**

PHASE ONE BOARD OF DIRECTORS

TORRES[®]



1870

THANK YOU FOR SUPPORTING PHASE ONE!

Tito's®



Handmade

VODKA

PROUD TO
SUPPORT
PHASE
ONE!

**SANTA
MONICA**



BREW WORKS

BEACH BREWED

Thank you for supporting PHASE ONE!

THANK YOU

GOLD WONG PHOTOGRAPHY

Eat^H

WWW.HEIRLOOMLA.COM



THANK YOU TO HEIRLOOM CATERING FOR SUPPORTING PHASE ONE.

Thank you for supporting Phase One!



MEADOWOOD
Napa Valley

www.meadowood.com



THE RESTAURANT

AT MEADOWOOD

THANK YOU FOR
SUPPORTING PHASE ONE!



S I N E G A L

E S T A T E

www.sinegalestate.com

PROUD TO SUPPORT PHASE ONE





FOUR SEASONS
Hotels and Resorts
PROUD TO SUPPORT PHASE ONE



PHASE
ONE

WELLNESS
SPONSOR

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH

“Never doubt that a small group of thoughtful, committed people can change the world; indeed, it's the only thing that ever has.”
Margaret Mead

ROYCE

Thank you for your dedication and vision devoted to this worthy cause.

The impact of your work is felt by many.

We are honored to have you as our friend.

LISE & ROBERT APPLEBAUM

Thank you
BROOKE AND KEN
for your ongoing support of
PHASE ONE,
which is such a wonderful
cause.

JENNA & TODD BINDER



THANK YOU
Marina Cohn
for your ongoing support of
PHASE ONE.

Leslie and Roger
Birnbaum

Thank you

PHASE ONE

*for making such a profound difference
in so many lives.*

*Your tireless courage, commitment
and dedication*

is truly an inspiration to us all.

The Bond Family

Jennifer, Larry, Juliana, Kelly and Johnny

Janet:

We salute your leadership,
dedication and commitment to
PHASE ONE.

You are an inspiration to all of us.

With much love,
The Sugerman and Carlson Families



**THE DAVIDOW
CHARITABLE FUND
PROUDLY
SUPPORTS
PHASE ONE.**



MARCI AND GREG FOSTER

Thank you for your devotion
to PHASE ONE – a reflection of
your generosity, love and compassion.

MARCI YOU ARE A TRUE SUPERSTAR!

With Love, Marci and Jeff Dinkin



*To our dear friends,
the Meadow's
and Valner's,
for their commitment
to PHASE ONE.*

*Love,
Amanda & Todd Eberstein*

*WE ARE SO PROUD TO SUPPORT OUR FRIENDS,
THE VALNERS,
AND PHASE ONE AND ALL THE GREAT WORK
IT DOES IN AN EFFORT TO CURE CANCER.*

XO,

NATALIE, NICHOLAS, CLAIRE, OLIVER & GEORGE

Marina

Your courage, strength and vision
inspire and encourage us all.
We are happy to support your efforts
to promote innovative cancer
research on behalf of

PHASE ONE

With love,
Cynthia & Ralph Finerman
Pam & Stan Maron

HERE'S TO THE CANCER FIGHTERS!

Thank you to:

Stacy & Alberto Valner,

Janet Lonner

**and PHASE ONE volunteers,
staff and clinicians.**

**We have benefited from your hard work and
dedication to fight cancer.**

Don and Eileen Coskey Fracchia

**2nd Street
BEAUTY
BOUTIQUE**

**For all that you do
to find the cure,
thank you.**

**Arlene & Richard Freeman
2nd Street Beauty**

**SO THRILLED TO BE THREE
OF THE ONES FOR ALL.**

**CONGRATS
TO ALL OF OUR FRIENDS
AT PHASE ONE.**

**LORI, SIMON AND
CHARLOTTE FURIE**

Maryann & Irwin Gold

are pleased to support the good work of

Phase One

*in advancing the fight
against cancer.*



**SO HAPPY
YOUR PHASES
CONTINUE!

XO HARBERT
FAMILY**

Missy,

WE ARE SO PROUD OF ALL
YOU DO TO SUPPORT THIS
PHENOMENAL ORGANIZATION!

Love Always,

JEN, ANDY, JOSH,
RYAN AND BROOKE



Darling Missy,

We are so proud of you...

**Your never ending support of
PHASE ONE,
and your commitment to make a
difference in people's lives is
what every parent hopes their
children shall work towards!**

All of our love,

Mom and Dad

**CONGRATULATIONS TO
ONE FOR ALL,
STACY VALNER,
AND ALL OF THOSE
THAT YOU SERVE!**

**WITH LOVE,
JEFF AND SANDY HUDSON**

**We are pleased
to support
Phase One!**

Deborah and Ivan Kallick

Stacy and Alberto,
ANOTHER SUCCESSFUL YEAR!
CONGRATULATIONS TO YOU
AND YOUR COMMITTEE...

LOVE,
Susan and Jon Krane

**We salute all the scientists and
volunteers of Phase One
who continue to
Fight On!**

the Libers

Carla * Rod * Ava * Samantha

We are proud to support
PHASE ONE.
Thank you for all you do
to find a cure.

Diana & Steve Maiman

WITH OUR SUPPORT



CHERRYL AND ROBERT MANGELS

KUDOS to

*Mieke Neumann
&
Stephanie Sandler*

**for their work for
PHASE ONE!**

LOVE,
Jeanne & Lenny Marks



**We're so proud to support
PHASE ONE.**

Congrats on another great gala.

Brad and Jodi Meadow

Congratulations
TO JANET & SUZETTE!
THE MEADOW FAMILY

MARCI FOSTER, JANET LONNER + PHASE ONE

AMAZING WOMEN + INCREDIBLE ORGANIZATION!

PROUD TO SUPPORT ALL

LIZ, TALYA, NOA, AARON, EDEN + KOBE NAFTALI

*We love you,
Marina.*



*Melanie & Mike
Neumann*

Congratulations

Janet and Suzette!

**Thank you and all our
friends at PHASE ONE
for all that you do!**

**With love and
admiration,**

Liz and Michael Nyman

STACY,

You continue to amaze us with your
accomplishments at
PHASE ONE
and in life.

Thank you for always being such a
great role model.

Love,

ELISSA AND RICK



PRESSED JUICERY PROUDLY SUPPORTS PHASE ONE

and appreciates Carly de Castro's
commitment to such a great cause.



pressed juicery™

Congratulations to

**STEPHANIE SANDLER,
MARINA COHN**

and the entire

PHASE ONE BOARD

*on another incredible and
successful event!*

Lots Of Love,

TRACY SANDLER



COLUMBUS PACIFIC

supports the important work of PHASE ONE.

IN MEMORY OF

Linda Bernstein

JILL & SANDY SIRULNICK



**CONGRATULATIONS
MIEKE!**

Thank you for your dedicated
leadership and support of

PHASE ONE

Your commitment to helping find a cure for
cancer makes a difference for so many!

**WITH LOVE,
Melanie & Tom Staggs**

ONE FOR ALL

Thank you to

Angela Kay

and

PHASE ONE

**for your dedication to
clinical cancer research.**

Ron and Penny Sue

**WE SUPPORT PHASE ONE
AND ALL THE LIVES IT WILL SAVE.**

THE SWALWELL FAMILY



Stephanie & Nick,

**THANK YOU FOR
ALL YOU DO.**

Martha & Ari

Thank you to
Phase One

for providing
Hope for All in the
fight against cancer.

CAROLYN AND JOHN TIPTON

Laura Fox and Ben Van de Bunt
are proud to support the
important work of
PHASE ONE.

**THANK YOU TO THE
MEADOWS AND VALNERS
FOR THE REMARKABLE WORK
YOU ARE DOING TO FIGHT CANCER.**

Joanie and Ken Weiss





Carol and Rand April
are proud to support

PHASE ONE
in its efforts to
fight cancer.

pulling together
for the best finish

Polsinelli is proud to support
Phase One Foundation because
we believe action creates
opportunity.

Together we make a difference.

polsinelli.com

The choice of a lawyer is an important decision and should not be based solely upon advertisements. Polsinelli PC, Polsinelli LLP in California.

We are thrilled to support

PHASE ONE

in your commitment to finding a cure.

Hillary and Lance Milken

Janet & Suzette

**A salute to your hard
work and dedication
to PHASE ONE!!**

**Thank you for inspiring
us to continue
the fight against cancer.**

Patty & Michael Rosenfeld

PHASE
ONE

**FRIENDS
SPONSOR**

AN EXTRAORDINARY EVENING SUPPORTING SOUTHERN CALIFORNIA CLINICAL TRIALS
AND INNOVATIVE CANCER RESEARCH



Château Boswell

In honor of
Emily and Jordan Bernstein.
So proud of you and all that you do for PHASE ONE.

Love,

Dana and Jonny Cohen
Andrea and Mike Feuerstein
Nicole and Brian Lando
Lauren and Blake Polisky

**Thank you to PHASE ONE for your
important work in cancer research**

Rhea Coskey



WWW.ESARTISTS.COM

*In honor of our family and friends who
faced cancer head on.*

Jon + Elana Gimbel



I support
PHASE ONE....
for all the possibilities!!

Love, Pat and Glenn

Stacy and Alberto Valner,

**THANK YOU FOR YOUR COMMITMENT
TO FIND A CURE FOR CANCER.**



Mark, Farrah, Blake & Brooke Weinstein

**LEARN MORE ABOUT PHASE ONE, INCLUDING OUR
LATEST GRANTS, UPCOMING EVENTS AND NEWS ABOUT
CANCER RESEARCH.**



@PHASEONELA #PHASEONE #ONEFORALL

THANK YOU FOR OUR MYSTERY GIFTS

23rd St Jewelers – A.O.C. – Adidas – Akasha Restaurant – Alexander Gray Optical – Alo Yoga – AMC Theaters – Anne Sisteron Fine Jewelry – AR Cucina – Ariel Gordon Jewelry – Arrive Clothing – Ashleigh Bergman Consulting – Atelier Swarovski – AVA MD – Avanesi – Baltaire Restaurant – Bandolier – Belmond El Encanto – Beltini – Bergdorf Goodman – Bestia – Beyond Yoga – Bottega Veneta – Brentwood General Store – Café Gratitude – Cake Monkey Bakery – Caudalie – Céline – Chanel – Charlie and Marcelle Jewelry – Chateau Boswell Winery – Cheryl Saban Designs – Clarisonic – Coral Tree Café – Debra Valner Designs – Dream Nails – Drybar – Edelweiss – EF Collection – Elwood Clothing – Elyse Walker – E.P. & L.P. – F10 Restaurants – Farmshop – Fauna Couture – FitBit – Forma Restaurant – Genghis Cohen – Georgie's at the Montage – Gloveworx – Google Home – Gratus – Graziela Gems – Gus's BBQ – Hands on Pilates – Healthy Spot – Heather Taylor Home – Hiptini – IMAX Corporation – James Perse – Jenni Kayne – Jerry's Famous Deli – Jill Roberts – John Hardy – Jouer Cosmetics – Juice Served Here – Karen Lazar Design – Kate Spade New York – Katie B. Photography – Kismet – Kye's Montana – Lady and the Sailor – Laird Family Estate – Lamill Coffee – Lana Unlimited – Lashes Eye Love – Liven Co – Loeffler Randall – Los Angeles Dodgers – Lotuff Leather – LUCQUES – Mainland Poke – Malia Mills – Malibu Farm – Merritt Eliot – Milestones by Ashleigh Bergman – MiniLuxe – Monica Vinader – MONROW Inc. – Montage Laguna Beach – NARS Cosmetics – Neiman Marcus – Nina Segal Jewelry – Olive + June – Paige – Parachute Home – Paychi Guh – Permanent Vacation – Picnic at Ascot – Plan Check Kitchen + Bar – Porta Via – Pressed Juicery – Rachel Katz Jewelry – Rebecca Minkoff – Red Bird – ROI Studio – Salazar – Shaffer LA – Shinola – Shupaca – Shutters on the Beach – SoulCycle – Speir Pilates – Stacey Todd – Stuart Weitzman – Sundry Clothing – SunLife Organics – Sweat NSK – Tamara Mellon – Tar & Roses – Tavern – Ted Baker London – Terry Snider Jewelry – the closet Sharon Segal – THE GREAT – THE NOW – The Red Room – The Spare Room – Tim Clarke Design – Tory Burch – Toscana – Valentino – Valley Brink Road – Vita Fede – Westside Head and Neck – Yumi Lashes

#PHASEONE #ONEFORALL

SPECIAL THANKS

AEG

Alyson Fine Marmur

Amanda Salvado

Anne Ackerman

Ashleigh Bergman

Ashly Smith

Bradley Meadow

Brinley Turner

Carly De Castro

Chef Christopher Kostow

Diane Allen

Elissa Phillips

Emily & Jordan Bernstein

Emily Current

Four Seasons Maui

Frankie & Barry Sholem

The Goldstein Family

Janet Kurtzman Lonner

Jill Roberts

John Rankin

Lauren Schiff

Leanna Creel

Linda Meadow

Linda Toth

Maggie Drake

Marci & Greg Foster

Mark Freeman

Mary & Steve Meadow

Maryann Gold

Meadowood Napa Valley

Merritt Elliot

Michele Steiner

Monica Lacy

Natalie Edmonds

Niki Valner

Robin Blau

Shelli & Irving Azoff

Sinegal Estate Winery

Stacy & Alberto Valner

Suzette Swalwell

Tema Schrage

Tim Clarke

PHASE

CANCER RESEARCH CURE

ONE

#PHASEONE #ONEFORALL